Table 2.
Univariate analyses of certain factors for bDFS in 121 patients treated with IMRT with or without regional hyperthermia.
| Variation | Patients (n) | 5-y (%) | p (Log-Rank Test) | Hazard Ratio * (95% Confidence Interval) |
|---|---|---|---|---|
| T stage | ||||
| T1–T2 | 99 | 87.4 | 0.6978 | 0.777 (0.217–2.786) |
| T3a | 22 | 84.0 | ||
| Gleason score | ||||
| ≤8 | 78 | 86.8 | 0.8710 | 0.913 (0.306–2.726) |
| ≥9 | 43 | 87.2 | ||
| Pretreatment PSA (ng/mL) | ||||
| ≤20 | 72 | 88.4 | 0.4478 | 0.668 (0.234–1.905) |
| >20 | 49 | 84.8 | ||
| Total ADT (months) | ||||
| ≤10 | 70 | 84.0 | 0.3344 | 0.569 (0.178–1.815) |
| >10 | 51 | 91.3 | ||
| Hyperthermia | ||||
| Yes | 70 | 89.8 | 0.2170 | 0.519 (0.180–1.497) |
| None | 51 | 82.9 | ||
| Hyperthermia | ||||
| CEM43T90 > 7 | 39 | 96.4 | 0.0296 | 0.144 (0.019–1.099) |
| None or CEM43T90 ≤ 7 | 82 | 82.4 |
* Hazard ratio and 95% confidence interval were calculated using the Wald test.